Pharma DECODED
Previous edition: 16 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Vanda Pharmaceuticals reports positive data from motion sickness trial
In the trial, only 10.4% and 18.3% of the subjects reported vomiting on the 170mg and 85mg doses, respectively.
Vanda Pharmaceuticals has reported positive outcomes from its second Phase III clinical trial of tradipitant, aimed at treating motion sickness.
Dubbed Motion Serifos, the double-blind, randomised, multicentre, placebo-controlled trial involved 316 participants with a history of motion sickness.
The study was conducted on boats in the coastal waters of the US.
Participants embarked on boat trips under varied sea conditions were given either 170mg or 85mg tradipitant, or placebo.
The impact of tradipitant in preventing vomiting was the trial’s primary endpoint.
Key secondary endpoints included the impact of the 85mg dose on vomiting and the drug's ability to prevent severe nausea and vomiting.
The study's findings reinforced previous results from two trials, demonstrating tradipitant's effectiveness in preventing severe nausea and vomiting associated with motion sickness.
Results also showed that both doses of tradipitant were significantly more effective than the placebo.
In the trial, only 10.4% and 18.3% of the subjects reported vomiting on the 170mg and 85mg doses, respectively, compared to 37.7% in the placebo arm.
This translates to a vomiting risk reduction by over 70% for the 170mg group and more than 50% for the 85mg group.
Furthermore, both doses of tradipitant were successful in achieving the secondary endpoint of preventing severe nausea and vomiting.
With these encouraging results, Vanda anticipates filing a new drug application for tradipitant, for prevention of vomiting induced by motion, with the US Food and Drug Administration in the fourth quarter of this year.
In December 2022, Vanda Pharmaceuticals reported data from a Phase II clinical trial of VQW-765 for the treatment of acute performance anxiety.
The placebo-controlled, randomised, multicentre, double-blind assessed VQW-765’s efficacy and safety in performance anxiety patients.
Latest news
KRAS inhibitors: The next frontier beckons
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma
The approval is based on results from the open-label, global, multi-centre, single-arm Phase II TRANSCEND FL clinical trial.
Takeda's dengue vaccine obtains WHO prequalification
The TAK-003 vaccine targets all four virus serotypes.
FDA rejects label expansion for Dynavax's hepatitis B vaccine
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
Tracking the opioid lawsuit settlements amidst calls for oversight
The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
The primary goal of the study is to measure progression-free survival.
Allucent receives grant for decentralised Covid-19 vaccine trial
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
In our previous edition
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Oil & Gas
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer